Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to learn about the clinical efficacy and safety of ganciclovir (GCV) capsules in the treatment of refractory moderate-to-severe allergic rhinitis. The main questions it aims to answer are: 1. Whether ganciclovir improve nasal symptoms and life quality in patients with refractory moderate-to-severe allergic rhinitis. 2. Whether ganciclovir is safe for the treatment of allergic rhinitis. Participants with refractory moderate-to-severe allergic rhinitis will be included in the trial based on the inclusion and exclusion criteria, and randomized into experimental and control groups. The two groups will be treated with blinded ganciclovir capsules or placebo for two weeks, with the background therapy of mometasone furoate aqueous nasal spray. A placebo is a look-alike capsule that contains no active drug. Nasal symptom scores, nasal secretions, blood samples and adverse events will be collected during the visits. Researchers will compare the experimental and control groups to see whether ganciclovir improve symptoms and is safe for the treatment of refractory moderate-to-severe allergic rhinitis.


Clinical Trial Description

Ganciclovir (GCV) is clinically used for the treatment of DNA viral infections. In clinical practice, we have found that patients with refractory AR have improved nasal symptoms after oral administration of ganciclovir. In clinical practice, we have found that patients with refractory AR have improved nasal symptoms after oral administration of ganciclovir. To further explore the role of GCV in the treatment of refractory allergic rhinitis, we have conducted an interventional non-randomised cohort study of GCV for refractory AR. The results found that 65% of all refractory AR patients included in the observation were effectively treated with GCV. Based on the previous discovery in the clinical practice, the conjecture is proposed that ganciclovir may improve symptoms in allergic rhinitis patients, in particular the patients with refractory moderate-to-severe allergic rhinitis. Thus, the randomized, double-blind, placebo-controlled clinical trial was designed to explore the validity of this hypothesis. The research involves three phases: screening phase(Day-14±2~0);baseline (Day1);treatment phase (Day1~14);follow-up phase (Day14~28). In the screening phase, anterior rhinoscopy, serum specific IgE test, skin prick test, total nasal symptom scores (TNSS), visual analogue scale (VAS) scores, Allergic Rhinitis Control Test (ARCT) score will be performed for participants. Participants who meet the inclusion and exclusion criteria will enter the treatment phase and receive the medication for two weeks. At the end of the treatment, researchers will follow participants for two weeks to track efficacy and safety. Researchers will collect participants' symptom scores, nasal secretions and blood. The biological specimens will be used to test for indicators that support the determination of therapeutic efficacy. Vital signs, blood routine examination, urine routines, liver function test, kidney function test and electrocardiograms will be measured for participants before and after treatment to assess the safety of ganciclovir. The data collected will be statistically analyzed to examine the clinical efficacy and safety of ganciclovir capsules in the treatment of refractory moderate-to-severe allergic rhinitis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06436534
Study type Interventional
Source Wuhan Union Hospital, China
Contact Jianjun Chen
Phone +86-13659851719
Email ylly80331@163.com
Status Recruiting
Phase N/A
Start date May 24, 2024
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT00770315 - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Phase 3
Completed NCT02486159 - The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture N/A
Completed NCT00771160 - MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED) Phase 3
Completed NCT00834119 - Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270) Phase 4
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT03758456 - HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human Phase 1
Completed NCT04645979 - A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
Completed NCT05122143 - Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers N/A
Completed NCT05901532 - Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis Phase 2
Terminated NCT02722083 - Exploratory Study for Allergy Relief Onset Phase 2
Recruiting NCT05656482 - Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT05922176 - Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
Completed NCT02679105 - Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy Phase 2/Phase 3
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A